Natera's Stock Drops: Competition and Patent Battles Intensify

Natera's stock dipped after Exact Sciences launched a new cancer detection test, intensifying competition in the genetic testing market. This follows a recent patent lawsuit loss, adding pressure on Natera. Despite these challenges, Natera's stock remains up year-to-date, reflecting long-term growth potential. Is this a buying opportunity or a sign of tougher times ahead for Natera? Hosted on Acast. See acast.com/privacy for more information.